Condition: Carcinoma, Hepatocellular · Liver Cell Carcinoma · Sponsor: Rutgers, The State University of New Jersey
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
This description comes directly from the study's public registry record.
Salma Jabbour, MD · 732-253-3961 · jabbousk@cinj.rutgers.edu
Patrick Boland, MD · 732-235-6628 · pb564@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05366829